R&D Policy

Federal investment in research fuels promising scientific discovery and supports the development and delivery of treatments and cures. FasterCures develops R&D policy solutions to ensure that there are both sufficient resources and a supportive environment for biomedical innovation.

We do this by:

  • championing federal investment that fuels scientific discovery and supports the development and delivery of new medical products
  • ensuring that the right tools, expertise and resources are accessible to scientists and regulators
  • creating opportunities for patient perspectives to inform scientific, regulatory and policy decision-making

We have advanced R&D policy by:

  • advocating for passage of the 21st Century Cures Act (H.R. 34, now P.L. 114-255) by testifying in Committee roundtables and educating legislators and stakeholders about the value and imperative of many of the law’s provisions, including new funding for the National Institutes of Health (NIH) and the Food and Drug Administration (FDA), support for patient centricity in medical product development, promoting the free flow of health data across IT systems and strengthening the FDA’s workforce
  • advancing solutions to help promising discoveries bridge the translation gap, including a series of publications that spotlights the importance of translational research in the therapeutic development process and significant support for the effort to create the National Center for Advancing Translational Sciences at the NIH through a Capitol Hill briefing of more than 100 Congressional staffers, patient advocates and R&D professionals
  • highlighting the importance of biomedical innovation to the health and economy of the United States through our Rx for Innovation project, including a report that compiles dozens of actionable recommendations from more than 150 thought leaders, an editorial in Science Translational Medicine and public panels at our annual meeting, Partnering for Cures

Initiatives include: